Overall market performance

According to statistics, the total sales* of China’s hospital pharmaceutical market were RMB 196.4 billion in 2017 Q3 (data source: China hospital drug statistical report of IQVIA, >=100 beds), growing by 6.2% year on year. Based on 12-month MAT (Moving Annual Total**), the MAT growth of 2017 Q3 was 6.2%.

*Sales: Purchase amount of hospital pharmacies

**MAT (Moving Annual Total): The total of figures over the course of the previous 12 months from a designated time node. It means the sales over the course from 2016 Q4 to 2017 Q3 here.

Market performance of multinational enterprises and local Chinese enterprises

The 2017 Q3 sales growth of multinational enterprises was 11.5% in China, significantly growing than the same period of last year, while that of Chinese enterprises was 4.6%, slightly down than the same period of last year. Pfizer, Yangtze River and AstraZeneca separately ranked the top three in enterprise quarterly sales and MAT sales rankings.

Top 10 Hospital Pharmaceutical Product Suppliers in China in 2017 Q3 (by Quarterly Sales)

Data source: IQVIA CHPA (China hospital drug statistical report), >=100 beds

Market performance of key therapeutic areas and major products

Categories and products

Seen from the therapeutic areas, in 2017 Q3, Chinese patent medicines achieved 1.7% MAT growth to reach RMB 134.6 billion MAT sales, ranking first among all drug categories; anti-infectives for systemic use achieved 5.0% MAT growth to reach RMB 114 billion MAT sales, ranking second; cardiovascular system drugs, antineoplastic drugs and immunomodulators, central nervous system drugs, blood and blood-forming organ drugs, respiratory system drugs, and musculoskeletal system drugs vigorously promoted the growth of the overall pharmaceutical market sales.

From the perspective of product rankings, Lipitor of Pfizer Inc. ranked first in quarterly sales rankings and MAT sales rankings. In those two rankings, Sanofi’s Plavix and Yangtze River Pharmaceutical’s Jialuoning separately ranked second and third. From the perspective of MAT growth, NBP, Sulperazon, Jialuoning, and Pulmicort Respules had significant growth, separately reaching 30.6%, 26.9%, 25.2% and 22.6%, while other products fluctuated in terms of the growth, but did not change much in the rankings.

Multinational enterprises

In 2017 Q3, multinational enterprises achieved 9.5% MAT growth to reach RMB 184.3 billion MAT sales, with quarterly sales reaching RMB 49.6 billion, growing by 11.5% year on year.

Among the newly marketed products of multinational enterprises in recent two years, the product Zytiga of Janssen Pharmaceutica NV ranked first in both quarterly sales rankings and MAT sales rankings (with the marketing time calculated according to the time when IQVIA first captured the product sales volume)

Chinese enterprises

Chinese enterprises achieved RMB 563 billion MAT sales in 2017 Q3, with MAT growth reaching 5.2%, and quarterly sales of RMB 146.8 billion, growing by 4.6% year on year.

Top 10 Therapeutic Areas in Hospital Drug Use in 2017 Q3 (by Quarterly Sales)

Data source: IQVIA CHPA (China hospital drug statistical report), >=100 beds

Top 10 Products in Hospital Drug Use in 2017 Q3 (by Quarterly Sales)

Data source: IQVIA CHPA (China hospital drug statistical report), >=100 beds

Also read: Review of Drug Use on Hospital Market in China in 2017 Q2

Register as Visitor to CPhI China 2018!